EPHA5 mediates trastuzumab resistance in HER2‐positive breast cancers through regulating cancer stem cell‐like properties-Reference-Cited by-全球学者库

EPHA5 mediates trastuzumab resistance in HER2‐positive breast cancers through regulating cancer stem cell‐like properties

Published:2019-01-08 Issue:4 Volume:33 Page:4851-4865
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Li Yongfei¹²³,Chu Jiahui¹,Feng Wanting¹,Yang Mengzhu¹,Zhang Yanhong¹,Zhang Yanqiu¹,Qin Ye²,Xu Juan⁴,Li Jun¹,Vasilatos Shauna N.²,Fu Ziyi¹⁴,Huang Yi²,Yin Yongmei¹

Affiliation:

1. Department of OncologyThe First Affiliated Hospital of Nanjing Medical University Nanjing China

2. Department of Pharmacology and Chemical BiologyUniversity of Pittsburgh Medical Center (UPMC) Hillman Cancer CenterUniversity of Pittsburgh Pittsburgh Pennsylvania USA

3. Department of Breast DiseasesJiangsu Province Hospital of Traditional Chinese Medicine (IMC)/Affiliated Hospital of Nanjing University of TCM Nanjing China

4. Nanjing Maternal and Child Health Medical InstituteAffiliated Obstetrics and Gynecology HospitalNanjing Medical University Nanjing China

Funder

National Outstanding Youth Science Fund Project of National Natural Science Foundation of China

Government of Jiangsu Province

Jiangsu Provincial Medical Youth Talent

Wu Jieping Medical Foundation

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.201701561RRRR

Reference45 articles.

1. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

2. Medicine: eyes on the target;Eisenstein M.;Nature,2015

3. Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

4. PKCα attenuates jagged‐l‐mediated notch signaling in ErbB‐2‐positive breast cancer to reverse trastuzumab resistance;Pandya K.;Clin. Cancer Res.,2016

5. Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eph receptors and ephrins in cancer progression;Nature Reviews Cancer;2023-11-23

2. IL-17 promotes melanoma through TRAF2 as a scaffold protein recruiting PIAS2 and ELAVL1 to induce EPHA5;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2023-10

3. The ALDH2, IGSF9, and PRDM16 Proteins as Predictive Biomarkers for Prognosis in Breast Cancer;Clinical Breast Cancer;2023-04

4. Advances in understanding the role and mechanisms of tumor stem cells in HER2-positive breast cancer treatment resistance (Review);International Journal of Oncology;2023-02-28

5. CRISPR/Cas9-based Gene Therapies for Fighting Drug Resistance Mediated by Cancer Stem Cells;Current Gene Therapy;2023-02